Very
nearly 66% of non-diabetic patients with Parkinson's disease (PD) might be insulin resistant, in spite of having normal
blood sugar. Researcher’s findings suggest that insulin resistance in PD is a
common and largely undetected problem, especially in patients who are
overweight.
Decreased
glucose tolerance has long been recognized as a potential risk factor for Parkinson's
disease, and there is expanding examination of insulin resistance as a
pathologic driver of neurodegeneration. The key link between the two conditions
appears to be insulin resistance, a potentially reversible condition that not
only predisposes individuals to type 2 diabetes (DM2) but is also related with neurodegeneration. However, the prevalence of insulin resistance in Parkinson's
disease is unknown.
Investigators tested 154 non-diabetic Parkinson's disease patients for fasting glucose and insulin to assess the prevalence of insulin resistance and to connect insulin resistance with other metabolic indicators, motor and non-motor symptoms of PD, and quality of life. Based a broadly used formula, known as the HOMA index, they determined how many of these patients had a reduced response to their own insulin. Among different estimations, their weight and height were recorded and their movement and cognitive performance were estimated.
Investigators tested 154 non-diabetic Parkinson's disease patients for fasting glucose and insulin to assess the prevalence of insulin resistance and to connect insulin resistance with other metabolic indicators, motor and non-motor symptoms of PD, and quality of life. Based a broadly used formula, known as the HOMA index, they determined how many of these patients had a reduced response to their own insulin. Among different estimations, their weight and height were recorded and their movement and cognitive performance were estimated.
Results demonstrated
that almost 66% of patients had undiagnosed insulin resistance, despite normal
fasting glucose and, in many cases, normal haemoglobin A1c, a test that is frequently
performed for type 1 and type 2 diabetes. Their information confirmed past examinations
that insulin resistance is more than double in obese compared with lean
individuals, but the investigators also found a substantially higher percentage
(41%) of lean Parkinson's disease patients with insulin resistance. They found
no correlation between insulin resistance and cognitive decline.
The potential effect
of this investigation is two-fold. Weight gain and obesity is a major public
health challenge and insulin resistance appears linked to body weight. These
findings could prompt to increase screening of PD patients to recognize and
correct this condition.
The second and
more particular impact is that identifying patients with insulin resistance
could allow for personalized medicine, whereby Parkinson’s disease patients
with insulin resistance may be treated with medications targeted to reverse the
condition. Study on the use of diabetic medications for PD, such as GLP-1
agonists like exenatide and liraglutide, is ongoing.
Now that, for
the first time, we understand how common insulin resistance is in non-diabetic
patients with Parkinson’s disease, we can start to address this public health
challenge. This increases the importance of finding new medications and way of
life mediations that can address this metabolic dysfunction with multiple
implications, from diabetes to neurodegenerative disorders like PD and Alzheimer's disease.
Contact details
Tiffany Hales
Program Manager | Diabetic 2018
Email id: diabetes@mehealthevents.org